Price
$56.70+23.08%1Y
1M-7.50%1Y+23.08%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above average7/10
Value53
Quality92
Momentum31
Growth28
P/E (TTM)15.4
Market Cap$110.27B
1Y Return+23.08%
5Y Return+0.48%
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $51.73B (-13.11%)
●Opdivo Ovantig grew +1711.11% YoY●Revlimid -62.71% YoY
SegmentLatestQoQYoY
- Sales Revenue Gross$16.93B-24.75%-14.83%
- Net Product Sales$11.17B-5.76%+2.59%
- Growth Brands$6.23B-9.19%+11.94%
- Legacy Brands$5.28B-1.64%-6.40%
- Eliquis$4.14B+10.44%+16.04%
- Opdivo$2.15B-15.24%-5.25%
- Orencia$818.0M-15.15%+6.23%
- Yervoy$651.0M-11.91%+4.33%
- Other Growth Brands$581.0M+13.04%+14.60%
- Reblozyl$555.0M-9.76%+16.11%
- Pomalyst Imnovid$513.0M-24.00%-22.04%
- Breyanzi$411.0M+14.48%+56.27%
- Revlimid$349.0M-39.30%-62.71%
- Alliance And Other Revenues$321.0M-+1.90%
- Camzyos$314.0M+6.08%+97.48%
- Opdualag$295.0M-1.34%+17.06%
- Other Revenues$227.0M-8.10%0.00%
- Opdivo Ovantig$163.0M+143.28%+1711.11%
- Other Legacy Brands$156.0M-11.86%-21.61%
- Zeposia$118.0M-26.71%+10.28%
- Alliance Revenues$94.0M-24.80%+6.82%
- Sprycel$73.0M-38.66%-58.29%
- Sotyktu$69.0M-13.75%+25.45%
- Cobenfy$56.0M+30.23%+107.41%
- Abraxane$50.0M-32.43%-52.38%
- Krazati$50.0M-5.66%+4.17%
- Abecma---
- Allianceandotherrevenues---
- Augtyro---
- Empliciti---
- In Line Products And New Product Portfolio---
- In Line Products---
- Inrebic---
- LOEProducts---
- Mature And Other Brands---
- New Product Portfolio---
- Onureg---
- Other Revenue Hedging Activities−$15.0M--